i-abiraterone acetate, Janssen Biotech, UBUKHULU, mCRPC, I-Niraparib
I-Niraparib ne-abiraterone acetate plus prednisone kuvunywe yi-FDA kumdlavuza wendlala yesinye we-BRCA oguquliwe we-metastatic castration-resistant
Agasti 2023: Inhlanganisela yomthamo ongaguquki we-niraparib ne-abiraterone acetate (Akeega, Janssen Biotech, Inc.), kanye ne-prednisone, kugunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-castration-resista.
Janssen Biotech, IsikhumbuzoTAL-1, i-myeloma eminingi, I-Talquetamab-tgvs, I-Talvey
I-Talquetamab-tgvs ithole ukugunyazwa okusheshisiwe kwe-myeloma eminingi ebuyele emuva noma ephikisayo.
Agasti 2023: I-Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) inikezwe ukugunyazwa okusheshayo yi-Food and Drug Administration yokwelapha abantu abadala abane-myeloma eminingi ebuyele emuva noma ephikisayo abaye badlula e-..
Janssen Biotech, I-MajesTEC-1, I-NCT03145181, i-teclistamab-cqyv, I-Tecvayli
I-Teclistamab-cqyv igunyazwe yi-FDA nge-myeloma eminingi ebuyele emuva noma ephikisayo.
Novemba 2022: I-bispecific B-cell maturation antigen (BCMA) yokuqala eqondiswe kwi-CD3 T-cell engager, i-teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), yanikezwa ukugunyazwa okusheshisiwe yi-Food and Drug Administration kumuntu omdala.
Izindlela zokwelapha ze-CAR-T, i-chimeric antigen receptors, China, i-ciltacabtagene autoleucel, Janssen Biotech, I-Legend biotech
I-CARVYKTI (ciltacabtagene autoleucel), I-BCMA-Directed CAR-T Therapy, ithola imvume ye-US FDA yokwelashwa kweziguli ezikhulile ezine-myeloma eminingi ebuyele emuva noma ephikisayo.
Mashi 2022: NgokukaJohnson & Johnson, indlela yokwelapha eyakhiwe inkampani kanye nozakwabo ozinze eChina i-Legend Biotech Corp yokwelapha uhlobo lomdlavuza wamangqamuzana amhlophe egazi kuvunywe yi-US Food and Drug Administrati.
I-BCMA, I-CARYKTI, i-ciltacabtagene autoleucel, i-ejenti ye-immunomodulatory, Janssen Biotech, i-proteasome inhibitor
I-Ciltacabtagene autoleucel igunyazelwe i-myeloma eminingi ebuyele emuva noma ephikisayo
Mashi 2022: Ngemva kwemigqa yokwelapha emine noma ngaphezulu yangaphambili, okuhlanganisa i-proteasome inhibitor (PI), i-immunomodulatory agent (IMiD), kanye ne-anti-CD38 monoclonal antibody, i-Food and Drug Administration igunyaze i-ciltacabtagene au.
Amgen, i-carfilzomib, I-Darzalex Faspro, dexamethasone, Janssen Biotech, I-Kyprolis, i-myeloma eminingi
I-Darzalex faspro, i-kyprolis, ne-dexamethasone igunyazwe yi-FDA nge-myeloma eminingi
Mashi 2022: I-Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) kanye ne-carfilzomib (Kyprolis, Amgen, Inc.) kanye ne-dexamethasone kugunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-relap.
UDaratumumab, I-Darzalex Faspro, dexamethasone, I-Hyaluronidase-fihj, Janssen Biotech, i-pomalidomide
I-Daratumumab ne-hyaluronidase-fihj kanye ne-pomalidomide ne-dexamethasone kuvunyelwe yi-FDA ekwelapheni i-myeloma eminingi
Agasti 2021: I-Daratumumab ne-hyaluronidase-fihj (i-Darzalex Faspro, i-Janssen Biotech, Inc.) zigunyazwe yi-Food and Drug Administration ngokuhlanganiswe ne-pomalidomide ne-dexamethasone ezigulini ezikhulile ezine-multiple my..